Form 4: Calidi Biotherapeutics Director Acquires Stock Options

Director George Peoples acquired non-qualified stock options for 20,217 shares of Calidi Biotherapeutics common stock.

Summary

• On October 15, 2024, a Form 4 filing revealed that George Peoples, a director of Calidi Biotherapeutics, Inc. (CLDI), acquired non-qualified stock options.
• The transaction occurred on September 20, 2024, with the options granted on October 11, 2024.
• Peoples received options to purchase 20,217 shares of common stock at an exercise price of $1.09 per share.
• The options vest in monthly installments over one year, starting from the grant date of September 20, 2024.
• The options expire on September 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates